Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
14 03 2019
Historique:
pubmed: 12 2 2019
medline: 9 4 2020
entrez: 12 2 2019
Statut: ppublish

Résumé

Focal adhesion tyrosine kinase (PTK2) is often overexpressed in human hepatocellular carcinoma (HCC), and several reports have linked PTK2 depletion and/or pharmacological inhibition to reduced tumorigenicity. However, the clinical relevance of targeting PTK2 still remains to be proven. Here, we present two highly selective and functional PTK2 proteolysis-targeting chimeras utilizing von Hippel-Lindau and cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 (cereblon-based) degrades PTK2 with a median DC

Identifiants

pubmed: 30739444
doi: 10.1021/acs.jmedchem.8b01826
doi:

Substances chimiques

Ligands 0
Protein Kinase Inhibitors 0
Recombinant Proteins 0
Focal Adhesion Kinase 1 EC 2.7.10.2
Focal Adhesion Protein-Tyrosine Kinases EC 2.7.10.2
PTK2 protein, human EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2508-2520

Auteurs

Johannes Popow (J)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Heribert Arnhof (H)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Gerd Bader (G)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Helmut Berger (H)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Alessio Ciulli (A)

Division of Biological Chemistry and Drug Discovery, School of Life Sciences, James Black Centre , University of Dundee , Dow Street , DD1 5EH Dundee , Scotland, U.K.

David Covini (D)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Christian Dank (C)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Teresa Gmaschitz (T)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Peter Greb (P)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Jale Karolyi-Özguer (J)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Manfred Koegl (M)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Darryl B McConnell (DB)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Mark Pearson (M)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Maria Rieger (M)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Joerg Rinnenthal (J)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Vanessa Roessler (V)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Andreas Schrenk (A)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Markus Spina (M)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Steffen Steurer (S)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Nicole Trainor (N)

Division of Biological Chemistry and Drug Discovery, School of Life Sciences, James Black Centre , University of Dundee , Dow Street , DD1 5EH Dundee , Scotland, U.K.

Elisabeth Traxler (E)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Corinna Wieshofer (C)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Andreas Zoephel (A)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Peter Ettmayer (P)

Boehringer Ingelheim RCV GmbH & Co KG , 1221 Vienna , Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH